300558 贝达药业
开盘竞价 11-20 09:30:00
资讯
新帖
简况
贝达药业(300558.SZ)：注射用MCLA-129获得临床试验批准通知书
智通财经网 · 11-19 19:32
贝达药业(300558.SZ)：注射用MCLA-129获得临床试验批准通知书
贝达药业最新公告：注射用MCLA-129获得临床试验批准通知书
证券之星 · 11-19 19:30
贝达药业最新公告：注射用MCLA-129获得临床试验批准通知书
贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押489.5万股，占总股本1.17%
证券之星 · 11-07
贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押489.5万股，占总股本1.17%
11月6日贝达药业现1笔折价22.15%的大宗交易 合计成交699.59万元
证券之星 · 11-06
11月6日贝达药业现1笔折价22.15%的大宗交易 合计成交699.59万元
贝达药业11月5日现1笔大宗交易 成交金额845.1万元
新浪证券-红岸工作室 · 11-05
贝达药业11月5日现1笔大宗交易 成交金额845.1万元
贝达药业11月4日现1笔大宗交易 成交金额1022.84万元
新浪证券-红岸工作室 · 11-04
贝达药业11月4日现1笔大宗交易 成交金额1022.84万元
瑞普晨创公布A轮融资，融资额超亿人民币，投资方为中国风投、贝达药业等
证券之星 · 11-03
瑞普晨创公布A轮融资，融资额超亿人民币，投资方为中国风投、贝达药业等
东海证券：给予贝达药业买入评级
证券之星 · 11-03
东海证券：给予贝达药业买入评级
贝达药业(300558.SZ)拟与瑞普晨创合作开发干细胞治疗业务 布局糖尿病治疗市场
智通财经 · 11-01
贝达药业(300558.SZ)拟与瑞普晨创合作开发干细胞治疗业务 布局糖尿病治疗市场
贝达药业最新公告：与杭州瑞普晨创签署战略合作协议 合作开发干细胞治疗业务
证券之星 · 11-01
贝达药业最新公告：与杭州瑞普晨创签署战略合作协议 合作开发干细胞治疗业务
阿斯利康骗保案余波未了：中国区“一把手”王磊配合调查 重磅肺癌药面临国产药“围剿”
ÿվ · 11-01
阿斯利康骗保案余波未了：中国区“一把手”王磊配合调查 重磅肺癌药面临国产药“围剿”
贝达药业10月31日现1笔大宗交易 成交金额1239.65万元
新浪证券-红岸工作室 · 10-31
贝达药业10月31日现1笔大宗交易 成交金额1239.65万元
贝达药业（300558）2024年三季报简析：营收净利润同比双双增长
证券之星 · 10-30
贝达药业（300558）2024年三季报简析：营收净利润同比双双增长
国金证券：给予贝达药业买入评级
证券之星 · 10-29
国金证券：给予贝达药业买入评级
图解贝达药业三季报：第三季度单季净利润同比增22.95%
证券之星 · 10-29
图解贝达药业三季报：第三季度单季净利润同比增22.95%
贝达药业(300558.SZ)发布前三季度业绩，净利润4.16亿元，增长36.61%
智通财经 · 10-28
贝达药业(300558.SZ)发布前三季度业绩，净利润4.16亿元，增长36.61%
贝达药业最新公告：前三季度净利润4.16亿元 同比增长36.61%
证券之星 · 10-28
贝达药业最新公告：前三季度净利润4.16亿元 同比增长36.61%
贝达药业(300558)9月30日股东户数3.26万户，较上期减少7.16%
证券之星 · 10-25
贝达药业(300558)9月30日股东户数3.26万户，较上期减少7.16%
贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押545万股，占总股本1.3%
证券之星 · 10-22
贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押545万股，占总股本1.3%
华昊中天通过港交所上市聆讯：已实现商业化，贝达药业等为股东
贝多财经 · 10-21
华昊中天通过港交所上市聆讯：已实现商业化，贝达药业等为股东
加载更多
公司概况
公司名称：
贝达药业股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-07
主营业务：
贝达药业股份有限公司主营业务为创新药物的生产与销售。公司主要产品和服务有贝安汀、贝美纳、凯美纳、赛美纳、伏美纳。公司明星产品凯美纳获得了国家知识产权局和世界专利组织联合颁发的中国专利金奖（两次）、我国工业界“奥斯卡奖”、中国工业大奖、人民网和中国药促会联合颁发的最具临床价值创新药奖、入选新中国70年卫生健康大事记等。荣获2022浙江省药学会科学技术特等奖。
发行价格：
17.57
{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":46.8,"timestamp":1732065381000,"preClose":46.95,"halted":0,"volume":0,"delay":0,"floatShares":417000000,"shares":418000000,"eps":1.0982,"marketStatus":"开盘竞价","marketStatusCode":1,"change":-0.15,"latestTime":"11-20 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":46.8,"askSize":26,"bidPrice":46.8,"bidSize":26,"shortable":0,"etf":0,"ttmEps":1.0982,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":46.95,"symbolType":"stock","openAndCloseTimeList":[[1732066200000,1732073400000],[1732078800000,1732086000000]],"highLimit":51.65,"lowLimit":42.26,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":418485885,"pbRate":3.49,"roa":"--","roe":"7.64%","epsLYR":0.83,"committee":0.16129,"marketValue":19585000000,"floatMarketCap":19524000000,"peRate":42.61519,"changeRate":-0.0032,"turnoverRate":0,"status":1},"requestUrl":"/m/hq/s/300558","defaultTab":"news","newsList":[{"id":"2484287912","title":"贝达药业(300558.SZ)：注射用MCLA-129获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2484287912","media":"智通财经网","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484287912?lang=zh_cn&edition=full","pubTime":"2024-11-19 19:32","pubTimestamp":1732015966,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)公告，公司到国家药品监督管理局(简称“NMPA”)签发的《药物临床试验批准通知书》(通知书编号：2024LP02606)，公司申报的注射用MCLA-129拟用于“晚期实体瘤(包括但不限于野生型结直肠癌、肝癌、头颈鳞癌、胰腺癌、原发不明腺癌以及鳞癌等晚期实体瘤)”的药物临床试验申请已获得NMPA批准。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK1576","BK1583","BK0060","03347","BK1141","300558"],"gpt_icon":0},{"id":"2484912764","title":"贝达药业最新公告：注射用MCLA-129获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2484912764","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484912764?lang=zh_cn&edition=full","pubTime":"2024-11-19 19:30","pubTimestamp":1732015827,"startTime":"0","endTime":"0","summary":"贝达药业公告，公司收到NMPA签发的《药物临床试验批准通知书》，公司申报的注射用MCLA-129拟用于晚期实体瘤的药物临床试验申请已获得NMPA批准。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900032257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK1583","BK1576","BK1141","300558","03347"],"gpt_icon":0},{"id":"2481456902","title":"贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押489.5万股，占总股本1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481456902","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481456902?lang=zh_cn&edition=full","pubTime":"2024-11-07 21:20","pubTimestamp":1730985630,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月7日公开信息显示，股东宁波凯铭投资管理合伙企业向山东省国际信托股份有限公司合计质押489.5万股，占总股本1.17%。质押详情见下表：截止本公告日，股东宁波凯铭投资管理合伙企业已累计质押股份6058.91万股，占其持股总数的75.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700035520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2481629496","title":"11月6日贝达药业现1笔折价22.15%的大宗交易 合计成交699.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481629496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481629496?lang=zh_cn&edition=full","pubTime":"2024-11-06 16:50","pubTimestamp":1730883017,"startTime":"0","endTime":"0","summary":"证券之星消息，11月6日贝达药业发生大宗交易，交易数据如下：大宗交易成交价格38.46元，相对当日收盘价折价22.15%，成交18.19万股，成交金额699.59万元，买方营业部为中信建投证券股份有限公司北京朝阳分公司，卖方营业部为中信建投证券股份有限公司北京朝阳分公司。近三个月该股共发生12笔大宗交易，合计成交4.11万手，折价成交12笔。截至2024年11月6日收盘，贝达药业报收于49.4元，上涨2.77%，换手率2.76%，成交量11.53万手，成交额5.63亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600028029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2481522281","title":"贝达药业11月5日现1笔大宗交易 成交金额845.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481522281","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481522281?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:01","pubTimestamp":1730797260,"startTime":"0","endTime":"0","summary":" 11月5日，贝达药业收涨2.39%，收盘价为48.07元，发生1笔大宗交易，合计成交量22.5万股，成交金额845.1万元。 第1笔成交价格为37.56元，成交22.50万股，成交金额845.10万元，溢价率为-21.86%，买方营业部为中信建投证券股份有限公司北京朝阳分公司，卖方营业部为中信建投证券股份有限公司北京朝阳分公司。 进一步统计，近3个月内该股累计发生11笔大宗交易，合计成交金额为1.41亿元。该股近5个交易日累计上涨2.71%，主力资金合计净流出9804.83万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-05/doc-incuyzvc1190687.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-05/doc-incuyzvc1190687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2480379224","title":"贝达药业11月4日现1笔大宗交易 成交金额1022.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480379224","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480379224?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:00","pubTimestamp":1730710800,"startTime":"0","endTime":"0","summary":" 11月4日，贝达药业收涨2.83%，收盘价为46.95元，发生1笔大宗交易，合计成交量28万股，成交金额1022.84万元。 第1笔成交价格为36.53元，成交28.00万股，成交金额1,022.84万元，溢价率为-22.19%，买方营业部为中信建投证券股份有限公司北京朝阳分公司，卖方营业部为中信建投证券股份有限公司北京朝阳分公司。 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为1.33亿元。该股近5个交易日累计下跌2.09%，主力资金合计净流出1.57亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-04/doc-incuwwwc2122442.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-04/doc-incuwwwc2122442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2480020350","title":"瑞普晨创公布A轮融资，融资额超亿人民币，投资方为中国风投、贝达药业等","url":"https://stock-news.laohu8.com/highlight/detail?id=2480020350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480020350?lang=zh_cn&edition=full","pubTime":"2024-11-03 19:27","pubTimestamp":1730633228,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP于10月31日公布的信息整理，杭州瑞普晨创科技有限公司公布A轮融资，融资额超亿人民币，参与投资的机构包括中国风投，贝达药业，联想创投，荷塘创投，贝利创投。瑞普晨创坚持前沿创新，自主知识产权的核心干细胞技术处于世界领先地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110300001653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2480814813","title":"东海证券：给予贝达药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480814813","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480814813?lang=zh_cn&edition=full","pubTime":"2024-11-03 09:48","pubTimestamp":1730598519,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏,伍可心近期对贝达药业进行研究并发布了研究报告《公司简评报告：业绩略超预期，恩沙替尼国际化进展顺利》，本报告对贝达药业给出买入评级，当前股价为45.66元。 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20241103/c663122202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["161027","300558"],"gpt_icon":0},{"id":"2480539888","title":"贝达药业(300558.SZ)拟与瑞普晨创合作开发干细胞治疗业务 布局糖尿病治疗市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2480539888","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480539888?lang=zh_cn&edition=full","pubTime":"2024-11-01 20:42","pubTimestamp":1730464943,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业 公告，公司拟与杭州瑞普晨创科技有限公司签署《战略合作协议》，双方将合作开发干细胞治疗业务，在人多能干细胞向胰岛细胞诱导分化技术领域展开深入合作。据悉，公司拟通过上述对瑞普晨创的投资及与其签署《战略合作协议》的方式，布局糖尿病治疗市场，并逐步进军细胞和基因治疗的广阔领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1205894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2480002791","title":"贝达药业最新公告：与杭州瑞普晨创签署战略合作协议 合作开发干细胞治疗业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2480002791","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480002791?lang=zh_cn&edition=full","pubTime":"2024-11-01 20:10","pubTimestamp":1730463008,"startTime":"0","endTime":"0","summary":"贝达药业公告，公司拟与杭州瑞普晨创科技有限公司签署《战略合作协议》，双方将合作开发干细胞治疗业务，在人多能干细胞向胰岛细胞诱导分化技术领域展开深入合作。同时，公司拟出资2000万元认缴瑞普晨创新增注册资本11.1111万元，投后占比0.9390%。公司关联人贝橙创投拟出资2000万元认缴瑞普晨创新增注册资本11.1111万元，投后占比0.9390%。公司关联人宁波六谷本次拟出资500万元认缴瑞普晨创新增注册资本2.7778万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100043318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2480079734","title":"阿斯利康骗保案余波未了：中国区“一把手”王磊配合调查 重磅肺癌药面临国产药“围剿”","url":"https://stock-news.laohu8.com/highlight/detail?id=2480079734","media":"ÿվ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480079734?lang=zh_cn&edition=full","pubTime":"2024-11-01 16:47","pubTimestamp":1730450844,"startTime":"0","endTime":"0","summary":"持续3年多的阿斯利康骗保案调查，在近日达到高潮。继多位公司前高管、大区经理、总监等相继接受调查后，阿斯利康全球官网在10月30日晚发布消息称，公司全球执行副总裁、国际业务主席及中国 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20241101/c663078114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","300558","BK0060","688217","688578"],"gpt_icon":0},{"id":"2479779272","title":"贝达药业10月31日现1笔大宗交易 成交金额1239.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479779272","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479779272?lang=zh_cn&edition=full","pubTime":"2024-10-31 16:40","pubTimestamp":1730364000,"startTime":"0","endTime":"0","summary":" 10月31日，贝达药业收涨1.50%，收盘价为46.06元，发生1笔大宗交易，合计成交量34.15万股，成交金额1239.65万元。 第1笔成交价格为36.30元，成交34.15万股，成交金额1,239.65万元，溢价率为-21.19%，买方营业部为中信建投证券股份有限公司北京朝阳分公司，卖方营业部为中信建投证券股份有限公司北京朝阳分公司。 进一步统计，近3个月内该股累计发生9笔大宗交易，合计成交金额为1.23亿元。该股近5个交易日累计上涨0.11%，主力资金合计净流出1.74亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-10-31/doc-incumwmy7260801.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-10-31/doc-incumwmy7260801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2479261370","title":"贝达药业（300558）2024年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2479261370","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479261370?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:30","pubTimestamp":1730241016,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期贝达药业发布2024年三季报。根据财报显示，贝达药业营收净利润同比双双增长。截至本报告期末，公司营业总收入23.45亿元，同比上升14.73%，归母净利润4.16亿元，同比上升36.6%。按单季度数据看，第三季度营业总收入8.44亿元，同比上升15.65%，第三季度归母净利润1.92亿元，同比上升22.95%。持有贝达药业最多的基金为圆信永丰兴源灵活配置混合A，目前规模为4.15亿元，最新净值1.7157，较上一交易日下跌3.52%，近一年下跌2.26%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000006647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"gpt_icon":0},{"id":"2479414253","title":"国金证券：给予贝达药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479414253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479414253?lang=zh_cn&edition=full","pubTime":"2024-10-29 11:54","pubTimestamp":1730174097,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司赵海春,袁维近期对贝达药业进行研究并发布了研究报告《扣非高增50%，核查通过，贝美纳FDA获批在即》，本报告对贝达药业给出买入评级，当前股价为47.75元。2024年3月，美国FDA已受理贝美纳用于ALK阳性的局部晚期或转移性非小细胞肺癌患者的一线治疗的上市申请。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为51.34。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900018824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"gpt_icon":0},{"id":"2479437169","title":"图解贝达药业三季报：第三季度单季净利润同比增22.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479437169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479437169?lang=zh_cn&edition=full","pubTime":"2024-10-29 01:28","pubTimestamp":1730136500,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业2024年三季报显示，公司主营收入23.45亿元，同比上升14.73%；归母净利润4.16亿元，同比上升36.6%；扣非净利润3.62亿元，同比上升50.12%；其中2024年第三季度，公司单季度主营收入8.44亿元，同比上升15.65%；单季度归母净利润1.92亿元，同比上升22.95%；单季度扣非净利润1.45亿元，同比下降4.88%；负债率38.81%，投资收益-650.68万元，财务费用3454.89万元，毛利率83.81%。筹资活动产生的现金流量净额变动幅度为-131.53%,原因:取得银行借款减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900000876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"gpt_icon":0},{"id":"2478435109","title":"贝达药业(300558.SZ)发布前三季度业绩，净利润4.16亿元，增长36.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478435109","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478435109?lang=zh_cn&edition=full","pubTime":"2024-10-28 23:46","pubTimestamp":1730130418,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)发布2024年三季度报告，该公司前三季度营业收入为23.45亿元，同比增长14.73%。归属于上市公司股东的净利润为4.16亿元，同比增长36.61%。归属于上市公司股东的扣除非经常性损益的净利润为3.62亿元，同比增长50.12%。基本每股收益为0.99元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300558"],"gpt_icon":0},{"id":"2478177939","title":"贝达药业最新公告：前三季度净利润4.16亿元 同比增长36.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478177939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478177939?lang=zh_cn&edition=full","pubTime":"2024-10-28 18:00","pubTimestamp":1730109650,"startTime":"0","endTime":"0","summary":"贝达药业发布2024年第三季度报告，前三季度实现营业收入23.45亿元，同比增长14.73%；归属于上市公司股东的净利润4.16亿元，同比增长36.61%。其中，第三季度实现营业收入8.44亿元，同比增长15.65%；归属于上市公司股东的净利润1.92亿元，同比增长22.95%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800025522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"gpt_icon":0},{"id":"2478603445","title":"贝达药业(300558)9月30日股东户数3.26万户，较上期减少7.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478603445","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478603445?lang=zh_cn&edition=full","pubTime":"2024-10-25 17:11","pubTimestamp":1729847514,"startTime":"0","endTime":"0","summary":"证券之星消息，近日贝达药业披露，截至2024年9月30日公司股东户数为3.26万户，较7月31日减少2517.0户，减幅为7.16%。在化学制药行业个股中，贝达药业股东户数高于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.13万户。从股价来看，2024年7月31日至2024年9月30日，贝达药业区间涨幅为34.57%，在此期间股东户数减少2517.0户，减幅为7.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500030249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"gpt_icon":0},{"id":"2477133295","title":"贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押545万股，占总股本1.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477133295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477133295?lang=zh_cn&edition=full","pubTime":"2024-10-22 21:29","pubTimestamp":1729603751,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业10月22日公开信息显示，股东宁波凯铭投资管理合伙企业向山东省国际信托股份有限公司合计质押545.0万股，占总股本1.3%。质押详情见下表：截止本公告日，股东宁波凯铭投资管理合伙企业已累计质押股份6114.41万股，占其持股总数的76.37%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200036188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"gpt_icon":0},{"id":"2477228078","title":"华昊中天通过港交所上市聆讯：已实现商业化，贝达药业等为股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2477228078","media":"贝多财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477228078?lang=zh_cn&edition=full","pubTime":"2024-10-21 10:16","pubTimestamp":1729476960,"startTime":"0","endTime":"0","summary":"近日，北京华昊中天生物医药股份有限公司通过港交所上市聆讯，并披露了聆讯后资料集（招股书）。其中，优替德隆注射液是华昊中天的核心产品，于2021年获得国家药监局批准上市，用于治疗复发或转移性晚期乳腺癌。2022年、2023年度和2024年前五个月，华昊中天的核心产品销量分别为18483瓶、90021瓶和38577瓶。本次上市前，唐莉和邱荣国直接及间接合计控制华昊中天29.47%的投票权。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-21/doc-incthspx2354898.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-21/doc-incthspx2354898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0060","300558","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","stockEarnings":[{"period":"1week","weight":-0.0662},{"period":"1month","weight":0.0341},{"period":"3month","weight":0.3111},{"period":"6month","weight":0.2385},{"period":"1year","weight":-0.1638},{"period":"ytd","weight":-0.0851}],"companyName":"贝达药业股份有限公司","boardCode":"AI0027","perCapita":"12790股","boardName":"医药制造业","registeredCapital":"41848万元","compareEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":0.0259},{"period":"3month","weight":0.1713},{"period":"6month","weight":0.0737},{"period":"1year","weight":0.0905},{"period":"ytd","weight":0.1247}],"survey":" 贝达药业股份有限公司主营业务为创新药物的生产与销售。公司主要产品和服务有贝安汀、贝美纳、凯美纳、赛美纳、伏美纳。公司明星产品凯美纳获得了国家知识产权局和世界专利组织联合颁发的中国专利金奖（两次）、我国工业界“奥斯卡奖”、中国工业大奖、人民网和中国药促会联合颁发的最具临床价值创新药奖、入选新中国70年卫生健康大事记等。荣获2022浙江省药学会科学技术特等奖。","serverTime":1732065386407,"listedPrice":17.57,"stockholders":"32616人(较上一季度减少7.16%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}